Kolexia
Fumet Jean David Oncologie médicale
Fumet Jean David
Oncologie médicale
Centre Georges-François Leclerc
Dijon, France
241 Activités
1.3 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du poumon Carcinome pulmonaire non à petites cellules Tumeurs du sein Métastase tumorale Carcinome pulmonaire à petites cellules Tumeurs de l'ovaire Tumeurs du côlon COVID-19

Collaborateurs

Voir plus
Ghiringhelli Francois
Ghiringhelli Francois
Centre Georges-François Leclerc, Dijon, France
Hennequin Audrey
Hennequin Audrey
Centre Georges-François Leclerc, Dijon, France
Bengrine-Lefevre Leila
Bengrine-Lefevre Leila
Centre Georges-François Leclerc, Dijon, France
Kaderbhai Coureche Guillaume
Kaderbhai Coureche Guillaume
Centre Georges-François Leclerc, Dijon, France

Industries

Voir plus
Pfizer
15 collaboration(s)
Dernière en 2023
B3TSI
12 collaboration(s)
Dernière en 2022
AstraZeneca
9 collaboration(s)
Dernière en 2023
Lilly
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
GUIDE2REPAIR: Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment
Essai Clinique (AstraZeneca)   12 février 2024
FOLFIRINOX3 P: Phase II Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy (FOLFIRINOX3 Pancréas)
Essai Clinique (Centre Georges-François Leclerc)   09 février 2024
FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.
Frontiers in oncology   30 novembre 2023
GYNET: A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
Essai Clinique (NETRIS Pharma)   24 novembre 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
BMC cancer   09 novembre 2023
IMMUNOs-SBRT: An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
Essai Clinique (Centre Georges-François Leclerc)   16 octobre 2023
KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM
Abstracts from the 18th Meeting of the European Association of Neuro-Oncology   08 septembre 2023
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
Nature medicine   10 août 2023
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
EBioMedicine   25 mai 2023
ESME-MBC: Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008
Essai Clinique (Seagen)   16 mars 2023